 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other May 15 Calls Today's Calls |
| Call Details | |||
| Abraxis Biosciences, Inc. Earnings Conference Call (Q1 2008) Thu, May 15, 2008, 11:30 am Eastern
| |||
| About Abraxis Biosciences, Inc. (NasdaqGS:ABII) | |||
| Abraxis Bioscience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. The company’s product pipeline includes clinical oncology and cardiovascular product candidates in various stages of testing and development. Its principal product includes Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. Abraxis BioScience’s other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity. In addition, the company offers Coroxane, which is in Phase II clinical studies for coronary restenosis and peripheral artery restenosis. It has strategic relationships with AstraZeneca UK Limited; Taiho Pharmaceutical Co., Ltd.; Biocon Limited; University of Southern California; Cenomed BioSciences, LLC; and Green Cross Corporation. The company was founded in 2007. It was formerly known as New Abraxis, Inc. and changed its name to Abraxis Bioscience, Inc. in 2007. The company is based in Los Angeles, California. | |||
More Info: | |||
